Research Pipeline

With many potential new therapies currently in clinical trials, our goal is to be the industry leader in specialty care. We remain focused on discovering scientific breakthroughs to address complex, debilitating diseases.

Explore highlights of our research and development pipeline across our five areas of focus.

Items marked with ^ are being developed in collaboration with Regeneron, ❅ are being developed in collaboration with Sangamo Therapeutics, ♕ are being developed in collaboration with Roche, ♢ are being developed in collaboration with SOBI, ✿ are being developed in collaboration with Revolution Medicines, ⚙ are being developed in collaboration with BioNtech, ⚜ are being developed in collaboration with Immunext, ✪ are being developed in collaboration with Denali, ➤ are being developed in collaboration with Lead Pharma and ♦ are being developed in collaboration with Principia Biopharma Inc. Items shown with a ✜ denote a Phase 1/2 trial. Items shown with a † denote a Phase 2/3 trial. Items shown with ▼ denote the INN in the US is cemiplimab-rwlc. Items shown with ♠ denote opt in rights product for which rights have not been exercised yet. Items shown with ❒ denote identification of out-licensing partner ongoing.

Product Candidate	Technology	Phase I	Phase II	Phase III	Current Phase
Rare Diseases
Eliglustat Gaucher disease Type 1, ERT switch Pediatric	small molecule				PHASE III
Avalglucosidase alfa Pompe disease	protein-based therapy				PHASE III
Venglustat Autosomal Dominant Polycystic Kidney Disease (ADPKD)	small molecule				PHASE III
Olipudase Alfa† Acid Sphingomyelinase Deficiency (ASMD)	protein-based therapy				PHASE II
Venglustat Fabry disease	small molecule				PHASE II
Venglustat Gaucher disease Type 3	small molecule				PHASE II
SAR339375 Alport Syndrome	miRNA-21				PHASE II
Rare Blood Disorders
Fitusiran Hemophilia A & B	RNAi				PHASE III
Fitusiran Hemophilia A & B - pediatric	RNAi				PHASE III
Sutimlimab Cold Agglutinin Disease	mAb to C1s				PHASE III
BIVV001♢ Hemophilia A	Extended Half Life Factor				PHASE III
ST400❅✜ Beta Thalassemia	ZFN gene editing				PHASE I/II
BIVV003❅✜ Sickle Cell Disease	ZFN gene editing				PHASE I/II
Sutimlimab Immune Thrombocytopenic Purpura	mAb to C1s				PHASE I
BIVV020 Immune Thrombocytopenic Purpura	mAb to C1s				PHASE I
Multiple Sclerosis/Neurology
Teriflunomide Relapsing Multiple Sclerosis - Pediatric	small molecule				PHASE III
Alemtuzumab Relapsing Remitting Multiple Sclerosis - Pediatric	mAb				PHASE III
SAR422459❒ Stargardt Disease	gene therapy				PHASE II
SAR442168♦ Multiple Sclerosis	BTK inhibitor				PHASE II
Venglustat Parkinson's disease with a GBA mutation	small molecule				PHASE II
SAR443060✪ Amyotrophic Lateral Sclerosis	RIPK1 inhibitor				PHASE I
SAR443060✪ Multiple Sclerosis	RIPK1 inhibitor				PHASE I
SAR441344⚜ Multiple Sclerosis	mAb				PHASE I
Oncology
Isatuximab 3L Relapsed Refractory Multiple Myeloma (ICARIA)	mAb	$Isatuximab 3L Relapsed Refractory Multiple Myeloma (ICARIA) - Phase I - 100% of progress$	$Isatuximab 3L Relapsed Refractory Multiple Myeloma (ICARIA) - Phase II - 100% of progress$	$Isatuximab 3L Relapsed Refractory Multiple Myeloma (ICARIA)- Phase III - 100% of progress$	PHASE III
Isatuximab 2L Relapsed Refractory Multiple Myeloma (IKEMA)	mAb	$Isatuximab Relapsed Refractory Multiple Myeloma - Phase I - 100% of progress$	$Isatuximab Relapsed Refractory Multiple Myeloma - Phase II - 100% of progress$	$Isatuximab Relapsed Refractory Multiple Myeloma - Phase III - 50% of progress$	PHASE III
Isatuximab 1L Newly Diagnosed Multiple Myeloma Transplant Ineligible (IMROZ)	mAb				PHASE III
Isatuximab Newly Diagnosed Multiple Myeloma Transplant Ineligible (GMMG)	mAb				PHASE III
Cemiplimab^▼ 2L Cervical Cancer	mAb				PHASE III
Cemiplimab^▼ Adjuvant in Cutaneous Squamous Cell Carcinoma (CSCC)	mAb				PHASE III
Cemiplimab^▼ 1L Non-small Cell Lung Cancer	mAb				PHASE III
Cemiplimab^▼ + Chemotherapy 1L Non-small Cell Lung Cancer	mAb				PHASE III
SAR408701 2-3L Non-Small Cell Lung Cancer	anti-body drug conjugate				PHASE III
Isatuximab + Cemiplimab^▼ Relapsed Refractory Multiple Myeloma	mAb	$isatuximab + Cemiplimab^ Relapsed Refractory Multiple Myeloma - Phase I - 100% of progress$	$isatuximab + Cemiplimab^ Relapsed Refractory Multiple Myeloma - Phase II - 50% of progress$	$isatuximab + Cemiplimab^ Relapsed Refractory Multiple Myeloma - Phase III - 0% of progress$	PHASE II
Isatuximab + Cemiplimab^▼ Lymphoma	mAb				PHASE II
Isatuximab + atezolizumab♕ Metastatic Colorectal Cancer	mAb				PHASE II
Isatuximab + atezolizumab♕ Solid Tumors	mAb				PHASE II
Isatuximab 1-2L Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) - Pediatrics	mAb				PHASE II
Cemiplimab^▼ 2-L Basal Cell Carcinoma (BCC)	mAb				PHASE II
SAR439859 Breast Cancer adjuvant	small molecule				PHASE II
SAR439859 2-3L Metastatic Breast Cancer	small molecule				PHASE I
SAR439459 Advanced Solid Tumors	mAb				PHASE I
REGN5458^♠ Relapsed Refractory Multiple Myeloma	bi-specific mAb	$REGN5458 Relapsed Refractory Multiple Myeloma - Phase I - 50% of progress$	$REGN5458 Relapsed Refractory Multiple Myeloma - Phase II - 0% of progress$	$REGN5458 Relapsed Refractory Multiple Myeloma - Phase III - 0% of progress$	PHASE I
REGN4018^♠ Ovarian Cancer	bi-specific mAb				PHASE I
SAR442720✿ Solid Tumors	small molecule				PHASE I
SAR440234 Leukemia	multi-specific mAb				PHASE I
SAR441000⚙ Solid Tumors	cytokine encoding mRNA				PHASE I
SAR439459 + cemiplimab^ Advanced Solid Tumors	mAb				PHASE I
SAR439859 + palbociclib Metastatic Breast Cancer	small molecule				PHASE I
cemiplimab +REGN4018^♠ Ovarian Cancer	mAb				PHASE I
SAR442085 Multiple Myeloma	mAb				PHASE I
REGN5459♠ Relapsed Refractory Multiple Myeloma	bi-specific mAb	$REGN5459 Relapsed Refractory Multiple Myeloma - Phase I - 25% of progress$	$REGN5459 Relapsed Refractory Multiple Myeloma - Phase II - 0% of progress$	$REGN5459 Relapsed Refractory Multiple Myeloma - Phase III - 0% of progress$	PHASE I
SAR442720✿ + cobimetinib Relapsed Refractory Solid Tumors	bi-specific mAb	$SAR442720 + cobimetinib Relapsed Refractory Solid Tumors - Phase I - 25% of progress$	$SAR442720 + cobimetinib Relapsed Refractory Solid Tumors - Phase II - 0% of progress$	$SAR442720 + cobimetinib Relapsed Refractory Solid Tumors - Phase III - 0% of progress$	PHASE I
THOR-707 Solid Tumors	non-alpha IL-2				PHASE I
SAR441000 + PD-1⚙ Solid Tumors	mRNA				PHASE I
Immunology
Dupilumab^ Atopic Dermatitis (6-11 years old)	mAb				PHASE III
Dupilumab^ Atopic Dermatitis (6 mo - 5 years old)	mAb				PHASE III
Dupilumab^ Asthma (6-11 years old)	mAb				PHASE III
Dupilumab^ Eosinophilic Esophagitis	mAb				PHASE III
Dupilumab^ Bullous pemphigoid	mAb				PHASE III
Dupilumab^ Prurigo nodularis	mAb				PHASE III
Dupilumab^ Chronic spontaneous urticaria	mAb				PHASE III
Sarilumab^ Giant Cell Arteritis	mAb				PHASE III
Sarilumab^ Polymyalgia Rheumatica	mAb				PHASE III
Dupilumab^ COPD	mAb				PHASE III
Dupilumab^ Grass Pollen Allergy	mAb				PHASE II
Dupilumab^ Peanut Allergy - Pediatric	mAb				PHASE II
SAR440340^ Asthma	mAb				PHASE II
SAR440340^ COPD	mAb				PHASE II
Sarilumab^ Polyarticular Juvenile Idiopathic Arthritis	mAb				PHASE II
Sarilumab^ Systemic Juvenile Arthritis	mAb				PHASE II
SAR156597^ Systemic Scleroderma	mAb				PHASE II
SAR440340^ Atopic Dermatitis	mAb				PHASE II
SAR441169➤ Psoriasis	small molecule				PHASE I
SAR441236 HIV	mAb				PHASE I
SAR443122✪ Inflammatory Indications	RIPK1 inhibitor				PHASE I

The agents mentioned here are investigational and have not been approved by the US Food and Drug Administration (FDA) or any other regulatory agency worldwide for the uses under investigation.

In addition to the candidates in clinical development, we are conducting earlier stage research in a range of therapeutic areas including genetic diseases such as cystic fibrosis, spinal muscular atrophy, and Lebers congenital amaurosis type 1. We have several programs in multiple sclerosis with molecules addressing areas of unmet need, using approaches such as immunomodulation, neuroprotection, and remyelination.

Avalglucosidase alfa clinical trial

Learn more about the ongoing phase 3 clinical trial for avalglucosidase alfa, an investigational enzyme replacement therapy being studied for the treatment of Pompe disease.

Sanofi’s R&D portfolio

The full Sanofi research pipeline focuses on finding innovative solutions to a variety of major public health challenges.

Research Pipeline

Rare Diseases

Rare Blood Disorders

Multiple Sclerosis/Neurology

Oncology

Immunology

Follow us